Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextroamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.76 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.76 |
| ▸ | MAOA | P21397 | 1/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.76 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | LAP3 | P28838 | 5/20 | 0.63 |
| ▸ | ANPEP | P15144 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL113682 | 1.00 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL31637605 | 0.94 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL16858761 | 0.94 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL17924971 | 0.94 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL10600513 | 0.90 | TAAR1 (0.61) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL4382899 | 0.89 | LAP3 (0.66) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL28990193 | 0.87 | TAAR1 (0.91) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL13747801 | 0.87 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL8859 | 0.87 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1560962 | 0.87 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8679535-B2 | Sustained release matrix systems for highly soluble drugs | ENDO PHARMACEUTICALS INC. (US) | 2014-03-25 | — | — | US | claimed |
| EP-1165054-A4 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD (BM) | 2005-02-09 | — | — | EP | claimed |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (BM) | 2003-10-16 | — | — | US | claimed |
| US-6555136-B2 | First, second and optionally third dosage units, with each dosage unit having a different drug release profile. | PHARMAQUEST, LTD. (BM) | 2003-04-29 | — | — | US | claimed |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (CA) | 2002-05-16 | — | — | US | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| US-12467031-B2 | Laser-assisted repositioning of a micro-object and culturing of an attachment-dependent cell in a microfluidic environment | BRUKER CELLULAR ANALYSIS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3597262-B1 | FORMULATION FOR INTRACUTANEOUS INJECTION | XERIS PHARMACEUTICALS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-114588124-A | Delayed release pharmaceutical composition | 江苏恒瑞医药股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-2526996-B1 | Formulation for intracutaneous injection | XERIS PHARMACEUTICALS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-9884021-B2 | Delayed release tablet with defined core geometry | JAGOTEC AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20160256396-A1 | Delayed Release Tablet With Defined Core Geometry | JAGOTEC AG (CH) | 2016-09-08 | — | — | US | disclosed |
| EP-0946151-A1 | ASCENDING-DOSE DOSAGE FORM | ALZA CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998023263-A1 | ASCENDING-DOSE DOSAGE FORM | ALZA CORPORATION (US) | 1998-06-04 | — | — | WO | disclosed |
| US-4693886-A | Osmotic device with inert core | ALZA CORPORATION (US) | 1987-09-15 | — | — | US | disclosed |
| US-4627971-A | Osmotic device with self-sealing passageway | ALZA CORPORATION (US) | 1986-12-09 | — | — | US | disclosed |
| US-4624847-A | Drug delivery device for programmed delivery of beneficial drug | ALZA CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| US-4609374-A | Osmotic device comprising means for governing initial time of agent release therefrom | ALZA CORPORATION (US) | 1986-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.